IP Library › Granted Patent US 12,195,462
Granted Patent B2
US 12,195,462 · App. 17/415,565 · Granted Jan 14, 2025

Organic compound

Inventors: Peng Li (New Milford, NJ); Qiang Zhang (Plainsboro, NJ); Robert Davis (San Diego, CA)
Assignee: INTRA-CELLULAR THERAPIES, INC.
C07D471/16A61K9/1647
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,462
App. No.
17/415,565
Granted
Jan 14, 2025
Kind
B2
Abstract

The invention relates to a particular substituted heterocycle fused gamma-carboline, in free, or pharmaceutically acceptable salt, and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT 2A receptor, the serotonin transporter (SERT), and/or pathways involving the dopamine D 1 and D 2 receptor signaling system.

Claims (39)

1. The compound of Formula I, in free or pharmaceutically acceptable salt form,

wherein the compound is in isolated or purified form.

2. The compound according to claim 1 , wherein the compound is in pharmaceutically acceptable acid addition salt form with an acid selected from hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic acid.

3. The compound according to claim 1 , wherein the compound is in toluenesulfonic acid addition salt form.

4. A pharmaceutical composition comprising the compound of Formula I:

in free or pharmaceutically acceptable salt form; in admixture with a pharmaceutically acceptable diluent or carrier.

5. The composition according to claim 4 , wherein the composition is formulated for sustained or delayed release, optionally as an injectable depot.

6. The composition according to claim 5 , wherein the composition further comprises a polymeric matrix.

7. The composition according to claim 6 , wherein the polymeric matrix is a biodegradable poly(d,l-lactide-co-glycolide) microsphere.

8. A method for the treatment of a central nervous system disorder, comprising administering to a patient in need thereof a composition according to claim 4 .

9. The method according to claim 8 , wherein the central nervous system disorder is a disorder involving serotonin 5-HT 2 A, dopamine D2 and/or D1 receptor system and/or the serotonin reuptake transporter (SERT) pathways.

10. The method according to claim 8 , wherein the central nervous system disorder is a disorder selected from the group consisting of obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, cephalic pain, social phobias, agitation in dementia, agitation in autism, dementia, mood disorders, obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), general anxiety disorder, social anxiety disorder, panic disorder, agoraphobia, compulsive gambling disorder, compulsive eating disorder, body dysmorphic disorder, hypochondriasis, pathological grooming disorder, kleptomania, pyromania, attention deficit-hyperactivity disorder (ADHD), attention deficit disorder (ADD), impulse control disorder, and combination thereof.

11. The method according to claim 8 , wherein the central nervous system disorder is a disorder selected from the following: (1) psychosis; (2) depression in a patient suffering from psychosis; (3) mood disorders associated with psychosis; (4) sleep disorders associated with psychosis; and (5) substance use disorders and/or substance-induced disorders.

12. The method according to claim 8 , wherein the central nervous system disorder is selected from obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), general anxiety disorder, social anxiety disorder, panic disorder, agoraphobia, compulsive gambling disorder, compulsive eating disorder, body dysmorphic disorder, hypochondriasis, pathological grooming disorder, kleptomania, pyromania, attention deficit-hyperactivity disorder (ADHD), attention deficit disorder (ADD), and impulse control disorder.

13. The method according to claim 8 , wherein the central nervous system disorder is depression, anxiety or a combination thereof.

14. The method according to claim 13 , wherein the depression and/or anxiety is acute depression and/or acute anxiety.

15. The method according to claim 8 , wherein the central nervous system disorder is acute anxiety.

16. The method according to claim 15 , wherein the acute anxiety is a short-duration anxious episode associated with generalized anxiety disorder, panic disorder, specific phobias, or social anxiety disorder, or social avoidance.

17. The method according to claim 8 , wherein the central nervous system disorder is acute depression.

18. The method according to claim 17 , wherein the acute depression is an acute major depressive episode, acute short-duration depressive episode, or acute recurrent brief depressive episode.

19. The method according to claim 8 , wherein the central nervous system disorder is treatment resistant depression.

20. The method according to claim 19 , wherein the treatment resistant depression is depression which has not responded to treatment with an antidepressant agent selected from a selective serotonin reuptake inhibitor (SSRI), a serotonin reuptake inhibitor (SRI), a tricyclic antidepressant, a monoamine oxidase inhibitor, a norepinephrine reuptake inhibitor (NRI), a dopamine reuptake inhibitor (DRI), an SRI/NRI, an SRI/DRI, an NRI/DRI, an SRI/NRI/DRI (triple reuptake inhibitor), a serotonin receptor antagonist, or any combination thereof.

21. The method according to claim 8 , wherein said patient is not responsive to or cannot tolerate the side effects from, treatment with selective serotonin reuptake inhibitors (SSRIs).

22. The method according to claim 21 , wherein the selective serotonin reuptake inhibitor is selected from citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.

23. The method according to claim 8 , wherein said patient is not responsive to or cannot tolerate the side effects from, treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs).

24. The method according to claim 23 , wherein the serotonin-norepinephrine reuptake inhibitor is selected from venlafaxine, sibutramine, duloxetine, atomoxetine, desvenlafaxine, milnacipran, and levomilnacipran.

25. The method according to claim 8 , wherein said patient is not responsive to or cannot tolerate the side effects from, treatment with antipsychotic agents.

26. The method according to claim 25 , wherein the antipsychotic agent is selected from clomipramine, risperidone, quetiapine, and olanzapine.

27. The method according to claim 8 , wherein the central nervous system disorder is bipolar depression or major depressive disorder.

28. The method according to claim 27 , wherein the central nervous system disorder is an acute major depressive episode associated with major depressive disorder.

29. The method according to claim 8 , wherein the patient is diagnosed as having suicidal ideation and/or suicidal tendencies.

30. The method according to claim 8 , wherein the treatment provides an acute response within less than 1 week, or from 1 to 7 days, or from 1 to 5 days, or from 1 to 3 days, after initial dosing of the compound.

31. The method according to claim 8 , wherein the compound of Formula I is in pharmaceutically acceptable acid addition salt form with an acid selected from hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic acid.

32. The method according to claim 8 , wherein the compound of Formula I is in toluenesulfonic acid addition salt form.

33. The method according to claim 8 , wherein the daily dosage of the compound of Formula I administered is 2.5 mg to 50 mg, based on the equivalent amount of free base form.

34. The composition according to claim 4 , wherein the compound of Formula I is in pharmaceutically acceptable acid addition salt form with an acid selected from hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic acid.

35. The composition according to claim 4 , wherein the compound of Formula I is in toluenesulfonic acid addition salt form.

36. The composition according to claim 4 , wherein the composition is a tablet or capsule for oral administration comprising 1 mg to 100 mg of the Compound of Formula I in free or pharmaceutically acceptable salt form, based on the equivalent amount of free base form.

37. The composition according to claim 36 , wherein the tablet or capsule comprises 2.5 to 50 mg of the Compound of Formula I in free or pharmaceutically acceptable salt form, based on the equivalent amount of free base form.

Continuity (2)
Provisional Application 62780804 · Dec 17, 2018
Related Publication 20220056030A1 · Feb 24, 2022
References Cited (114)
US 4238607A · Rajagopalan · 1980 [cited by applicant]
US 4389330A · Tice et al. · 1983 [cited by applicant]
US 4530840A · Tice et al. · 1985 [cited by applicant]
US 4849246A · Schmidt · 1989 [cited by applicant]
US 5114976A · Norden · 1992 [cited by applicant]
US 5151419A · Perenyi et al. · 1992 [cited by applicant]
US 5538739A · Bodmer et al. · 1996 [cited by applicant]
US 6544559B2 · Mesens et al. · 2003 [cited by applicant]
US 6548493B1 · Robichaud et al. · 2003 [cited by applicant]
US 6552017B1 · Robichaud et al. · 2003 [cited by applicant]
US 6699852B2 · Robichaud et al. · 2004 [cited by applicant]
US 6713471B1 · Robichaud et al. · 2004 [cited by applicant]
US 6849619B2 · Robichaud et al. · 2005 [cited by applicant]
US 6929803B2 · Wong et al. · 2005 [cited by applicant]
US 7071186B2 · Robichaud et al. · 2006 [cited by applicant]
US 7081455B2 · Robichaud et al. · 2006 [cited by applicant]
US 7183282B2 · Robichaud et al. · 2007 [cited by applicant]
US RE39679E · Robichaud et al. · 2007 [cited by applicant]
US RE39680E · Robichaud et al. · 2007 [cited by applicant]
US 7238690B2 · Robichaud et al. · 2007 [cited by applicant]
US 7592454B2 · Lee et al. · 2009 [cited by applicant]
US 7998971B2 · Barlow et al. · 2011 [cited by applicant]
US 8309722B2 · Tomesch et al. · 2012 [cited by applicant]
US 8598119B2 · Mates et al. · 2013 [cited by applicant]
US 8641148B2 · Fey et al. · 2014 [cited by applicant]
US 8648077B2 · Tomesch et al. · 2014 [cited by applicant]
US 8779139B2 · Tomesch et al. · 2014 [cited by applicant]
US 8791138B2 · Seeman et al. · 2014 [cited by applicant]
US 8993572B2 · Mates et al. · 2015 [cited by applicant]
US 9168258B2 · Mates et al. · 2015 [cited by applicant]
US 9199995B2 · Tomesch et al. · 2015 [cited by applicant]
US 9315504B2 · Tomesch et al. · 2016 [cited by applicant]
US 9371324B2 · Mates et al. · 2016 [cited by applicant]
US 9393192B2 · Yam et al. · 2016 [cited by applicant]
US 9428506B2 · Mates et al. · 2016 [cited by applicant]
US 9586960B2 · Tomesch et al. · 2017 [cited by applicant]
US 9616061B2 · Mates et al. · 2017 [cited by applicant]
US 9708322B2 · Li et al. · 2017 [cited by applicant]
US 9745300B2 · Mates et al. · 2017 [cited by applicant]
US 9751883B2 · Tomesch et al. · 2017 [cited by applicant]
US 9956227B2 · Vanover et al. · 2018 [cited by applicant]
US 10072010B2 · Li et al. · 2018 [cited by applicant]
US 10077267B2 · Mates et al. · 2018 [cited by applicant]
US 10117867B2 · Mates et al. · 2018 [cited by applicant]
US 10118926B2 · Koolman et al. · 2018 [cited by applicant]
US 10177867B2 · Fair et al. · 2019 [cited by applicant]
US 10179776B2 · Davis et al. · 2019 [cited by applicant]
US 10221176B2 · Tomesch et al. · 2019 [cited by applicant]
US 10245260B2 · Yao et al. · 2019 [cited by applicant]
US 10322134B2 · Vanover et al. · 2019 [cited by applicant]
US 10363200B2 · Li · 2019 [cited by applicant]
US 10533015B1 · Tusche et al. · 2020 [cited by applicant]
US 10654854B2 · Li et al. · 2020 [cited by applicant]
US 10668097B1 · Yao et al. · 2020 [cited by applicant]
US 10716786B2 · Li et al. · 2020 [cited by applicant]
US 10799500B2 · Yao et al. · 2020 [cited by applicant]
US 10906906B2 · Li et al. · 2021 [cited by applicant]
US 10961245B2 · Li et al. · 2021 [cited by applicant]
US 11014925B2 · Li et al. · 2021 [cited by applicant]
US 11053245B2 · Mates et al. · 2021 [cited by applicant]
US 11124504B2 · Mates et al. · 2021 [cited by applicant]
US 11332469B2 · Mittelman et al. · 2022 [cited by applicant]
US 11376249B2 · Li et al. · 2022 [cited by applicant]
US 11427587B2 · Li et al. · 2022 [cited by applicant]
US 11844757B2 · Yao et al. · 2023 [cited by applicant]
US 20060178362A1 · Robichaud et al. · 2006 [cited by applicant]
US 20150038519A1 · Mates et al. · 2015 [cited by applicant]
US 20150080404A1 · Mates et al. · 2015 [cited by applicant]
US 20160159787A1 · Linz et al. · 2016 [cited by applicant]
US 20200392135A1 · Wennogle et al. · 2020 [cited by applicant]
US 20210009592A1 · Li et al. · 2021 [cited by applicant]
US 20210093634A1 · Snyder et al. · 2021 [cited by applicant]
US 20210145829A1 · Li et al. · 2021 [cited by applicant]
US 20210163481A1 · Li et al. · 2021 [cited by applicant]
US 20220048910A1 · Li et al. · 2022 [cited by applicant]
US 20220056031A1 · Li et al. · 2022 [cited by applicant]
US 20220160704A2 · Torralva · 2022 [cited by applicant]
US 20220184072A1 · Davis et al. · 2022 [cited by applicant]
US 20220296591A1 · Li et al. · 2022 [cited by applicant]
US 20240165111A1 · Yao et al. · 2024 [cited by applicant]
WO WO2017117514 · 2017 [cited by applicant]
WO WO2020132605 · 2020 [cited by applicant]
Current Medicinal Chemistry (2005) 12, 23-49. [cited by examiner]
Darmani, N. A., et al., “Do Functional Relationships Exist Between 5-HT1A and 5-HT2 Receptors?,” Pharmacology and Biochemistry & Behavior, vol. 36, p. 901-906, (1990). [cited by applicant]
International Search Report for International Patent Application PCT/US2019/066894, prepared by the International Search Authority, date mailed Feb. 23, 2020, 2 pages. [cited by applicant]
Lee, T., et al. “Novel, Highly Potent, Selective 5-HT2A/D2 Receptor Antagonists as Potential Atypical Antipsychotics,” Bioorg. Med. Chem. Lett. vol. 13, pp. 767-770, (2003). [cited by applicant]
Aiken, C., “An Overview of Atypical Antipsychotics for Bipolar Depression,” published on Jan. 3, 2020 at https://www.psychiatrictimes.com/view/overview-atypical-antipsychotics-bipolar-depression, 11 pages. [cited by applicant]
Angst et al. “Prevalence and Characteristics of Undiagnosed Bipolar Disorders in Patients With a Major Depressive Episode”, Arch Gen Psychiatry, vol. 68(8), p. 701-709, (2011). [cited by applicant]
Davis et al., “ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes,” Expert Review of Neurotherapeutics, vol. 16, No. 6, pp. 601-614 (2016). [cited by applicant]
Davis et al., “ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders,” Clinical Trials in Alzheimer's Disease (CTAD) Congress 2014 (2014) (poster presentation). [cited by applicant]
Davis et al., “Rationale for the Development of Low Doses of ITI-007 for the Treatment of Behavioral Disturbances Associated with Dementia,” The Journal of Prevention of Alzheimer's Disease, 2(4):302 (2015) (Clinical Tr… [cited by applicant]
Davis, et al., “ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers,” Psychopharmacology, vol. 232, pp. … [cited by applicant]
Gramigna, J, “Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders,” American Society of Clinical Psychopharmacology Annual Meeting, Jun. 2, 2020, 3 pages. [cited by applicant]
Harbert, C.A. et al., “Neuroleptic Activity in 5-Aryltetrahydro-y-carbolines”, J. Med. Chem., vol. 23, pp. 635-643 (1980). [cited by applicant]
Hlavinka, E., “Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo,” Medpage Today, 7 pages, (2020); https://www.medpagetoday.com/meetingcoverage… [cited by applicant]
Khorana, N., et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin Receptors”, Bioorganic & Medicinal Chemistry, vol. 11, pp. 717-722, p. 718 Table 1, (2003). [cited by applicant]
Lammers, et al., “Risperidone Long-acting Injection in Schizophrenia Spectrum Illnesses Compared to First Generation Depot Antipsychotics in an Outpatient Setting in Canada,” BMC Psychiatry, vol. 13, No. 155, 9 pages, (… [cited by applicant]
Li et al., “Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders”, Journal of Medicinal Chemistr… [cited by applicant]
Lieberman, J.A., et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,” Biol. Psychiatry, vol. 79, No. 12, pp. 952-961, (2015). [cited by applicant]
Makadia et al., “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymers (Basel), vol. 3, No. 3, pp. 1377-1397, (2011). [cited by applicant]
Marek, G.J., et al., “Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorder,” Neuropsychopharmacology, (2003), vol. 28, pp. 402-412. [cited by applicant]
Medisorb Fact Sheet in Medisorb Microspheres Technology (Jan. 2009) at https://static.secure.website/wscfus/6472891/uploads/Medisorb.pdf (retrieved from the internet May 18, 2020) (Year: 2009). [cited by applicant]
Noble, F., et al., “The opioid receptors as targets for drug abuse medication,” British Journal of Psychology, vol. 172, pp. 3964-3979, (2015). [cited by applicant]
O'Gorman, et al., “Lumateperone (ITI-007): A Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders,” Poster P.1.g.038, European College of Neuropsychopharmacology (ECNP)… [cited by applicant]
Pubchem, CID-9953107, p. 3, pp. 1-9 (2006). [cited by applicant]
Rainer, M.K., “Risperidone long-acting injection: a review of its long term safety and efficacy,” Neuropsychiatric Disease and Treatment, vol. 4, No. 5, pp. 919-927 (2008). [cited by applicant]
Renner, J.A., Jr., “Management of Psychiatric Medications in Patients Receiving Buprenorphine/Naloxone,” PCSS MAT Training Providers' Clinical Support System for Medical Assisted Treatment, Last Updated: Nov. 28, 2013, … [cited by applicant]
Snyder, G.L., et al., “Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission,” Psychopharmacology, vol. 232, p. 605-621 (2015) Published online Aug. 2014, DOI 10.1007/s00213-014… [cited by applicant]
Vanover, et al., “Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia,” Neuropsychopharmacology 44:598-605, (2019). [cited by applicant]
Friedman, M., “Current and Future Drug Treatment for Posttraumatic Stress Disorder Patients,” Psychiatric Annals Journal, vol. 28, No. 8, pp. 464-468, (1998). [cited by applicant]
Intra-Cellular Therapies, Inc., “Corporate Presentation” (Sep. 24, 2019), downloaded from https://ir.intracellulartherapies.com/static-files/93b08960-f01c-4864-aa22-8cadb3539753 (last accessed Mar. 13, 2023). [cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Additional Results from Phase 1/11 Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia,” Intra-Cellular Therapies, Press Release Date: N… [cited by applicant]
PubChem, Open Chemistry Database, PubChem SID 103920954, PubChem CID 90655118, (2011), 6 pages. [cited by applicant]
PubChem, Open Chemistry Database, Compound Summary for CID-22036753, pp. 4, (2007), 12 pages. [cited by applicant]